A Phase 3 interventional study of 25 mg Ontamalimab and 75 mg Ontamalimab in Crohn's Disease and Ulcerative Colitis, sponsored by Shire. Completed at 419 sites in 37 countries. Open to participants aged 16 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-06-21.
Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 86 studies in Crohn Disease by Takeda — 12 open to participants now, 14 under way, 7 of them phase 3. Crohn Disease · Takeda.
Among the 86 studies in Crohn Disease by Takeda, this one is the 6th largest by enrollment of the 51 interventional ones that give a count, is one of 9 that started in 2018, is one of 25 in phase 3, and was the 32nd registered.
1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.
Browse Crohn Disease studies →12 of the 86 studies in Crohn Disease by Takeda are open now, in 12 countries. Recruiting first, the newest first:
Takeda · Sites in United Kingdom
Ages 18–75
Takeda · Sites in United States, Belgium, Bulgaria and 11 more countries
Ages 2–17
Takeda · Sites in United States, China, Czechia and 5 more countries
Ages 18–75
Takeda · Sites in United States
Ages 18–80
Takeda · Sites in United States, Belgium, Bulgaria and 13 more countries
Ages 2–17
By country, each count listing its studies:
Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.
This study: 16 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
86 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 14 · Phase 3 25 · Phase 4 10
First in 2000; this study’s year is marked. 9 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 557 is above the median of 67 across 1,261 interventional studies indexed under Crohn Disease.
Median enrollment 100 across the 51 interventional studies, 319 across the 34 observational. Of the 66 that completed or were terminated, 37 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Shire, one of the names counted as Takeda. Under that name alone:
Shire is the lead sponsor of 351 studies on the registry; 2 are open to participants now.
Of its 48 completed or terminated interventional studies of FDA-regulated products, 48 (100%) have results posted.
6 of the studies in Crohn Disease by Takeda that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06227910Phase 3TakedaA Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease | 2027-06-08 |
| NCT04779320Phase 3TakedaA Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD) | 2027-09-13 |
| NCT06233461TakedaA Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease | 2027-02-17 |
| NCT06581328TakedaA Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting | 2027-05-01 |
| NCT06045754TakedaA Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease | 2027-06-28 |
Add all 6 to your calendar (.ics) → With an account.
Among the 86 studies in Crohn Disease by Takeda, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and tolerability of long-term treatment with ontamalimab in participants with moderate to severe Ulcerative Colitis (UC) or Crohn's disease (CD)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants with Ulcerative Colitis (UC):
Participants must have been enrolled previously in study SHP647-301 (NCT03259334), SHP647-302 (NCT03259308), and are in the treatment period of Study SHP647-303, completed the early termination (ET) or Week 52 visit in maintenance study SHP647-303 (NCT03290781), had responded to ontamalimab treatment (in the induction and/or maintenance studies), and meet one of the following criteria:
a. Participants are on placebo at the maintenance study ET or Week 52 visit: they received ontamalimab in the induction studies and fulfilled the maintenance study response criteria, OR b. Participants have received ontamalimab at the maintenance study ET or Week 52 visit: i) Clinical composite score that has decreased by >or=2 points and >or=30%, with an accompanying decrease in the subscore for RB >or=1 point or a subscore for RB \<or=1, compared to the baseline value for induction studies, and/or ii) Composite score that has decreased by >or=30% and >or=3 points compared to the baseline value for induction studies.
Participants with Crohn's Disease:
Participants must have been enrolled previously in Study SHP647-305 (NCT03559517) or SHP647-306 (NCT03566823) and are in the treament period of Study SHP647-307 (NCT03627091), completed the ET or Week 52 visit in maintenance study SHP647-307, had responded to ontamalimab treatment (in the induction or maintenance studies) and meet one of the following criteria:
i) CDAI score that has decreased by >or=100 points at EOT visit compared to the baseline value for induction studies, and/or ii) SES-CD that has decreased by >or=25% compared to the baseline value for induction studies.
Exclusion Criteria:
Participants with UC:
Participants with Crohn's Disease:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 25 milligrams (mg) of ontamalimab solution for injection subcutaneously (SC), every 4 weeks (Q4W), for up to 3 years.
Drug: 25 mg Ontamalimab
Participants received 25 mg of ontamalimab solution for injection SC, Q4W, and later progressed to receive 75 mg in a similar manner for up to 5.79 years.
Drug: 25 mg Ontamalimab · Drug: 75 mg Ontamalimab
Participants received 75 mg of ontamalimab solution for injection SC, Q4W, for up to 5.79 years.
Drug: 75 mg Ontamalimab
Participants received 25 mg of ontamalimab solution for injection SC, Q4W, for up to 3 years.
Drug: 25 mg Ontamalimab
Participants received 25 mg of ontamalimab solution for injection SC, Q4W, and later progressed to receive 75 mg in a similar manner for up to 5.79 years.
Drug: 25 mg Ontamalimab · Drug: 75 mg Ontamalimab
Participants received 75 mg of ontamalimab solution for injection SC, Q4W, for up to 5.79 years.
Drug: 75 mg Ontamalimab
Ontamalimab SC solution for injection
Also known as: PF-00547659, SHP647
Ontamalimab SC solution for injection
Also known as: SHP647, PF-00547659
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent AEs (TEAEs) were defined as AEs with start dates or worsening dates at the time of or following the first exposure to investigational product.
Time frame: From first dose of study drug up to end of study [EOS] (up to 5.79 years)
Number of Participants With Serious Infections
Serious infections were defined as any infections that were life-threatening or those requiring hospitalization or intravenous antibiotics based on the investigator's assessment.
Time frame: From first dose of study drug up to EOS (up to 5.79 years)
Number of Participants With Notable Changes in Clinical Laboratory Parameters Over Time
Clinical laboratory assessments included hematology, serum chemistry and urinalysis. Any notable changes in the clinical laboratory value over time based on the investigator interpretation were reported.
Time frame: From first dose of study drug up to EOS (up to 5.79 years)
Number of Participants With Discernible Changes in Electrocardiogram (ECG) Over Time
ECG included heart rhythm, heart rate, QRS intervals, QT intervals, RR intervals and corrected QT (QTc) intervals parameters measurement. Any discernible changes in the ECG value over time based on investigator interpretation were reported.
Time frame: From first dose of study drug up to EOS (up to 5.79 years)
Number of Participants With Discernible Changes in Vital Signs Over Time
Vital sign assessments included blood pressure, pulse, respiratory rate, and temperature. Any discernible changes in vital signs over time per investigator interpretation were reported.
Time frame: From first dose of study drug up to EOS (up to 5.79 years)
Number of Participants With Ulcerative Colitis With Treatment Response Over Time
Treatment response over time was defined as clinical composite score that has decreased by greater than or equal to (≥2) points and ≥30 percentage (%), with an accompanying decrease in the sub score for rectal bleeding (RB) ≥1 point or a subscore for RB ≤ 1, and/or composite score that has decreased by ≥30% and ≥3 points compared to the baseline value for induction studies. The clinical composite score is a measure consisting of sub scores RB (0-3) plus stool frequency (0-3) with higher scores indicating more severe disease. With the implementation of amendment 4 of the protocol the study became a single arm study with all participants receiving the 75 mg dose of ontamalimab. Hence, only those UC participants who were receiving the 75 mg dose of ontamalimab every 4 weeks and participating in amendment 4 of the protocol were analyzed in this outcome measure.
Time frame: Up to 5.79 years
Number of Participants With Crohn's Disease With Treatment Response Over Time
Treatment response over time=Crohn's Disease Activity Index(CDAI)score that has decreased ≥100 points and/or simple endoscopic score for Crohn's disease(SES-CD)that has decreased by ≥25%,both compared to baseline value for induction studies.SES-CD is simple scoring system with 4 endoscopic variables measured in same 5 ileocolonic segments as CD index of severity. Overall values on SES-CD range from 0-56,higher values=more severe disease.4 endoscopic variables are scored from 0-3 in each bowel segment:ileum,right/transverse/left colon,rectum. Presence \& size of ulcers(none=0;diameter 0.1-0.5centimeter(cm)=1;0.5-2cm=2;\>2cm=3);extent of ulcerated surface(none=0;\<10%=1;10%-30%=2; \>30%= 3);extent of affected surface(none=0;\<50%=1;50%-75%=2;\>75%=3);Presence \& type of narrowing (none=0;single can be passed=1;multiple can be passed=2;cannot be passed=3).
Time frame: Up to 5.79 years
Participants took part in the study at 225 investigative sites in 33 countries from 27 February 2018 to 13 December 2023.
| Milestone | UC: Ontamalimab 25 mg | UC: Ontamalimab 25 mg Then 75 mg | UC: Ontamalimab 75 mg | CD: Ontamalimab 25 mg | CD: Ontamalimab 25 mg Then 75 mg | CD: Ontamalimab 75 mg |
|---|---|---|---|---|---|---|
| Started | 89 | 159 | 268 | 5 | 10 | 26 |
| Completed | 0 | 117 | 129 | 0 | 6 | 12 |
| Not completed | 89 | 42 | 139 | 5 | 4 | 14 |
| Withdrew: Adverse event | 18 | 3 | 13 | 0 | 0 | 5 |
| Withdrew: Death | 0 | 0 | 3 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 42 | 21 | 66 | 3 | 3 | 5 |
| Withdrew: Physician decision | 14 | 8 | 19 | 0 | 0 | 2 |
| Withdrew: Site terminated by sponsor | 1 | 0 | 3 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 2 | 0 | 2 | 0 | 0 | 1 |
| Withdrew: Pregnancy | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 12 | 6 | 24 | 1 | 1 | 0 |
| Withdrew: Reason not specified | 0 | 4 | 8 | 0 | 0 | 1 |
An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Treatment-emergent AEs (TEAEs) were defined as AEs with start dates or worsening dates at the time of or following the first exposure to investigational product.
| Participants | UC: Ontamalimab 25 mg | UC: Ontamalimab 25 mg Then 75 mg | UC: Ontamalimab 75 mg | CD: Ontamalimab 25 mg | CD: Ontamalimab 25 mg Then 75 mg | CD: Ontamalimab 75 mg |
|---|---|---|---|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) | 67 | 122 | 203 | 4 | 8 | 17 |
Serious infections were defined as any infections that were life-threatening or those requiring hospitalization or intravenous antibiotics based on the investigator's assessment.
| Participants | UC: Ontamalimab 25 mg | UC: Ontamalimab 25 mg Then 75 mg | UC: Ontamalimab 75 mg | CD: Ontamalimab 25 mg | CD: Ontamalimab 25 mg Then 75 mg | CD: Ontamalimab 75 mg |
|---|---|---|---|---|---|---|
| Number of Participants With Serious Infections | 5 | 4 | 17 | 0 | 0 | 0 |
Clinical laboratory assessments included hematology, serum chemistry and urinalysis. Any notable changes in the clinical laboratory value over time based on the investigator interpretation were reported.
| Participants | UC: Ontamalimab 25 mg | UC: Ontamalimab 25 mg Then 75 mg | UC: Ontamalimab 75 mg | CD: Ontamalimab 25 mg | CD: Ontamalimab 25 mg Then 75 mg | CD: Ontamalimab 75 mg |
|---|---|---|---|---|---|---|
| Number of Participants With Notable Changes in Clinical Laboratory Parameters Over Time | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) |
ECG included heart rhythm, heart rate, QRS intervals, QT intervals, RR intervals and corrected QT (QTc) intervals parameters measurement. Any discernible changes in the ECG value over time based on investigator interpretation were reported.
| Participants | UC: Ontamalimab 25 mg | UC: Ontamalimab 25 mg Then 75 mg | UC: Ontamalimab 75 mg | CD: Ontamalimab 25 mg | CD: Ontamalimab 25 mg Then 75 mg | CD: Ontamalimab 75 mg |
|---|---|---|---|---|---|---|
| Number of Participants With Discernible Changes in Electrocardiogram (ECG) Over Time | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) |
Vital sign assessments included blood pressure, pulse, respiratory rate, and temperature. Any discernible changes in vital signs over time per investigator interpretation were reported.
| Participants | UC: Ontamalimab 25 mg | UC: Ontamalimab 25 mg Then 75 mg | UC: Ontamalimab 75 mg | CD: Ontamalimab 25 mg | CD: Ontamalimab 25 mg Then 75 mg | CD: Ontamalimab 75 mg |
|---|---|---|---|---|---|---|
| Number of Participants With Discernible Changes in Vital Signs Over Time | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) |
Treatment response over time was defined as clinical composite score that has decreased by greater than or equal to (≥2) points and ≥30 percentage (%), with an accompanying decrease in the sub score for rectal bleeding (RB) ≥1 point or a subscore for RB ≤ 1, and/or composite score that has decreased by ≥30% and ≥3 points compared to the baseline value for induction studies. The clinical composite score is a measure consisting of sub scores RB (0-3) plus stool frequency (0-3) with higher scores indicating more severe disease. With the implementation of amendment 4 of the protocol the study became a single arm study with all participants receiving the 75 mg dose of ontamalimab. Hence, only those UC participants who were receiving the 75 mg dose of ontamalimab every 4 weeks and participating in amendment 4 of the protocol were analyzed in this outcome measure.
| Participants | UC: Ontamalimab 25 mg Then 75 mg | UC: Ontamalimab 75 mg |
|---|---|---|
| Number of Participants With Ulcerative Colitis With Treatment Response Over Time | 116 | 129 |
Treatment response over time=Crohn's Disease Activity Index(CDAI)score that has decreased ≥100 points and/or simple endoscopic score for Crohn's disease(SES-CD)that has decreased by ≥25%,both compared to baseline value for induction studies.SES-CD is simple scoring system with 4 endoscopic variables measured in same 5 ileocolonic segments as CD index of severity. Overall values on SES-CD range from 0-56,higher values=more severe disease.4 endoscopic variables are scored from 0-3 in each bowel segment:ileum,right/transverse/left colon,rectum. Presence \& size of ulcers(none=0;diameter 0.1-0.5centimeter(cm)=1;0.5-2cm=2;\>2cm=3);extent of ulcerated surface(none=0;\<10%=1;10%-30%=2; \>30%= 3);extent of affected surface(none=0;\<50%=1;50%-75%=2;\>75%=3);Presence \& type of narrowing (none=0;single can be passed=1;multiple can be passed=2;cannot be passed=3).
| Participants | CD: Ontamalimab 25 mg Then 75 mg | CD: Ontamalimab 75 mg |
|---|---|---|
| Number of Participants With Crohn's Disease With Treatment Response Over Time | 6 | 12 |
Collected over From first dose of study drug up to EOS (up to 5.79 years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| UC: Ontamalimab 25 mg | 0/89 (0%) | 15/89 (16.9%) | 47/89 (52.8%) |
| UC: Ontamalimab 25mg Then 75 mg | 0/159 (0%) | 21/159 (13.2%) | 109/159 (68.6%) |
| UC: Ontamalimab 75mg | 3/268 (1.1%) | 46/268 (17.2%) | 155/268 (57.8%) |
| CD: Ontamalimab 25 mg | 1/5 (20%) | 2/5 (40%) | 3/5 (60%) |
| CD: Ontamalimab 25 mg Then 75 mg | 0/10 (0%) | 2/10 (20%) | 8/10 (80%) |
| CD: Ontamalimab 75 mg | 0/26 (0%) | 4/26 (15.4%) | 14/26 (53.8%) |
| Event | UC: Ontamalimab 25 mg | UC: Ontamalimab 25mg Then 75 mg | UC: Ontamalimab 75mg | CD: Ontamalimab 25 mg | CD: Ontamalimab 25 mg Then 75 mg | CD: Ontamalimab 75 mg |
|---|---|---|---|---|---|---|
| DeathGeneral disorders | 0/89 | 0/159 | 1/268 | 1/5 | 0/10 | 0/26 |
| Drug eruptionSkin and subcutaneous tissue disorders | 0/89 | 0/159 | 0/268 | 1/5 | 0/10 | 0/26 |
| Acoustic neuromaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/89 | 0/159 | 0/268 | 0/5 | 1/10 | 0/26 |
| Calculus urinaryRenal and urinary disorders | 0/89 | 1/159 | 0/268 | 0/5 | 1/10 | 0/26 |
| Renal colicRenal and urinary disorders | 0/89 | 0/159 | 0/268 | 0/5 | 1/10 | 0/26 |
| Tendon injuryInjury, poisoning and procedural complications | 0/89 | 0/159 | 0/268 | 0/5 | 1/10 | 0/26 |
| Colitis ulcerativeGastrointestinal disorders | 6/89 | 3/159 | 10/268 | 0/5 | 0/10 | 0/26 |
| Anal fistulaGastrointestinal disorders | 0/89 | 0/159 | 0/268 | 0/5 | 0/10 | 1/26 |
| EnterocolitisGastrointestinal disorders | 0/89 | 0/159 | 0/268 | 0/5 | 0/10 | 1/26 |
| ProctitisGastrointestinal disorders | 0/89 | 1/159 | 1/268 | 0/5 | 0/10 | 1/26 |
| Event | UC: Ontamalimab 25 mg | UC: Ontamalimab 25mg Then 75 mg | UC: Ontamalimab 75mg | CD: Ontamalimab 25 mg | CD: Ontamalimab 25 mg Then 75 mg | CD: Ontamalimab 75 mg |
|---|---|---|---|---|---|---|
| Corona virus infectionInfections and infestations | 2/89 | 40/159 | 57/268 | 0/5 | 2/10 | 4/26 |
| Colitis ulcerativeGastrointestinal disorders | 22/89 | 21/159 | 28/268 | 0/5 | 0/10 | 0/26 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 3/89 | 10/159 | 13/268 | 0/5 | 2/10 | 1/26 |
| Asthma-chronic obstructive pulmonary disease overlap syndromeRespiratory, thoracic and mediastinal disorders | 0/89 | 0/159 | 0/268 | 1/5 | 0/10 | 0/26 |
| Back painMusculoskeletal and connective tissue disorders | 1/89 | 11/159 | 10/268 | 0/5 | 2/10 | 1/26 |
| Blood pressure increasedInvestigations | 0/89 | 1/159 | 1/268 | 1/5 | 0/10 | 0/26 |
| BronchitisInfections and infestations | 0/89 | 9/159 | 8/268 | 0/5 | 2/10 | 0/26 |
| Colon adenomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/89 | 1/159 | 0/268 | 1/5 | 0/10 | 0/26 |
| ConstipationGastrointestinal disorders | 0/89 | 1/159 | 3/268 | 1/5 | 0/10 | 0/26 |
| Dental cariesGastrointestinal disorders | 1/89 | 0/159 | 1/268 | 1/5 | 0/10 | 1/26 |
The Safety Set included all participants who received at least 1 dose of investigational product (IP) in the SHP647-304 study.
| Age, Categorical(Participants) | UC: Ontamalimab 25 mg | UC: Ontamalimab 25 mg Then 75 mg | UC: Ontamalimab 75 mg | CD: Ontamalimab 25 mg | CD: Ontamalimab 25 mg Then 75 mg | CD: Ontamalimab 75 mg | Total |
|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 2 | 7 | 0 | 1 | 1 | 11 |
| Between 18 and 65 years | 87 | 148 | 239 | 4 | 9 | 25 | 512 |
| >=65 years | 2 | 9 | 22 | 1 | 0 | 0 | 34 |
| Sex: Female, Male(Participants) | UC: Ontamalimab 25 mg | UC: Ontamalimab 25 mg Then 75 mg | UC: Ontamalimab 75 mg | CD: Ontamalimab 25 mg | CD: Ontamalimab 25 mg Then 75 mg | CD: Ontamalimab 75 mg | Total |
|---|---|---|---|---|---|---|---|
| Female | 29 | 67 | 111 | 1 | 5 | 14 | 227 |
| Male | 60 | 92 | 157 | 4 | 5 | 12 | 330 |
| Ethnicity (NIH/OMB)(Participants) | UC: Ontamalimab 25 mg | UC: Ontamalimab 25 mg Then 75 mg | UC: Ontamalimab 75 mg | CD: Ontamalimab 25 mg | CD: Ontamalimab 25 mg Then 75 mg | CD: Ontamalimab 75 mg | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 5 | 12 | 15 | 0 | 1 | 2 | 35 |
| Not Hispanic or Latino | 84 | 146 | 251 | 5 | 9 | 24 | 519 |
| Unknown or Not Reported | 0 | 1 | 2 | 0 | 0 | 0 | 3 |
| Race (NIH/OMB)(Participants) | UC: Ontamalimab 25 mg | UC: Ontamalimab 25 mg Then 75 mg | UC: Ontamalimab 75 mg | CD: Ontamalimab 25 mg | CD: Ontamalimab 25 mg Then 75 mg | CD: Ontamalimab 75 mg | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 2 | 4 | 0 | 0 | 1 | 7 |
| Asian | 7 | 14 | 24 | 1 | 0 | 0 | 46 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Black or African American | 0 | 2 | 4 | 0 | 0 | 2 | 8 |
| White | 77 | 135 | 231 | 4 | 9 | 23 | 479 |
| More than one race | 2 | 2 | 3 | 0 | 0 | 0 | 7 |
| Unknown or Not Reported | 2 | 4 | 2 | 0 | 1 | 0 | 9 |
Showing the first 100 of 419 sites across 37 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Feb 2018 to primary completion in Dec 2023, 69 months.
Results were first posted in Jun 2024, 6 months after primary completion.
Of 70 industry-sponsored phase 3 interventional studies under Crohn Disease, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 69. This study's 69 months is above that.
Counting every sponsor, half of 88 studies reached it within 49 months; a quarter within 36 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ontamalimab